^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    YTS104

    i
    Other names: YTS104, S104, LILRB4 STAR-T
    Associations

    News

    Trials
    Company:
    Beijing Qingyi Taike Pharma, BriSTAR Immunotech
    Drug class:
    ILT-3 inhibitor
    Related drugs:
    Associations

    News

    Trials
    6ms
    LILRB4 represents a promising target for immunotherapy by dual targeting tumor cells and myeloid-derived suppressive cells in multiple myeloma. (PubMed, Haematologica)
    In conclusion, our study elucidates that LILRB4 is an ideal biomarker and promising immunotherapy target for high-risk MM. LILRB4-STAR-T cell immunotherapy is promising against tumor cells and immunosuppressive tumor microenvironment in MM.
    Journal • IO biomarker • Tumor cell
    |
    LILRB4 (Leukocyte Immunoglobulin Like Receptor B4)
    |
    YTS104
    over1year
    YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=8, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital
    New P1 trial
    |
    LILRB4 (Leukocyte Immunoglobulin Like Receptor B4)
    |
    cyclophosphamide • YTS104